Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Discover the top 10 high-yield stocks for June 2025! Learn how to boost income with dividend growth, strong financials, and ...

Arvinas, Inc. (NASDAQ: ARVN) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...

In the 599-patient study, those on Wegovy alone lost about 7.9 pounds of muscle, while those on a combination of Regeneron's trevogrumab and Wegovy lost up to 4.2 pounds. Sanofi to buy US biopharma ...

Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer Inc. closed 26.70% short of its 52-week high of $31.54, which the company achieved on July 30th.

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like JAKK, GDOT, SIG, ROCK and PFE hold promise.

In the assessment of 12-month price targets, analysts unveil insights for BioNTech, presenting an average target of $138.7, a ...